Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
about
Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasiaPotentiating effects of GHRH analogs on the response to chemotherapy.Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines.Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1aThe contribution of growth hormone to mammary neoplasiaPotentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonistsInsulin-like growth factors and insulin: at the crossroad between tumor development and longevity.Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.Growth hormone-releasing hormone receptor splice variant 1 is frequently expressed in oral squamous cell carcinomas.Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
P2860
Q33939652-42DF53AF-457C-4C56-A94F-143DB2A40E04Q34621536-3E561CA2-3008-40F2-9791-0A8EC38D360FQ35565027-3C90F41A-12D5-469E-B462-3EAC9DF97569Q36696448-F4F338DD-0F01-4B00-9C23-8B0F43F87C58Q37016373-C43185B1-E725-47BC-8916-C30361A00091Q37078157-12C152A1-284D-454A-8B99-84CB4E93770EQ37495105-B7B18461-1E3E-4C8B-935E-683B492BD051Q37994048-2046CA44-9607-470C-A8CA-3A355A070374Q38977467-00BE671F-08E8-4867-8FC5-4009CBF02682Q39201247-FF2672CA-0117-4FCF-BF06-AC21060FE194Q39317388-0B6B18F3-0928-4800-B00E-8D1F5F326971Q39375139-13C341C9-DA19-4F0A-87E5-3083D899EC19Q39499342-B68897D0-861D-4173-BF6E-6BF34D760792Q41817287-E9E71354-1AC5-486E-8599-BDADC48F81AFQ42330184-507DA1F8-A3DF-413E-A9DA-F16CF9DC9CE5Q48828353-417FC54E-E135-46C4-A7EF-869109B4DD4A
P2860
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Potentiation of mammary cancer ...... easing hormone with docetaxel.
@ast
Potentiation of mammary cancer ...... easing hormone with docetaxel.
@en
type
label
Potentiation of mammary cancer ...... easing hormone with docetaxel.
@ast
Potentiation of mammary cancer ...... easing hormone with docetaxel.
@en
prefLabel
Potentiation of mammary cancer ...... easing hormone with docetaxel.
@ast
Potentiation of mammary cancer ...... easing hormone with docetaxel.
@en
P2093
P2860
P50
P356
P1476
Potentiation of mammary cancer ...... leasing hormone with docetaxel
@en
P2093
Elmar Heinrich
Florian Hohla
Frank Koester
Jozsef L Varga
Stefan Buchholz
P2860
P304
P356
10.1073/PNAS.0610860104
P407
P577
2007-01-29T00:00:00Z